8MM Myelofibrosis Epidemiology Analysis and Forecast 2021-2022 & 2031: Understand the Magnitude of Myelofibrosis by MIPSS70+ v2.0 Risk Categories, Mutations, and Anemia – ResearchAndMarkets.com

8MM Myelofibrosis Epidemiology Analysis and Forecast 2021-2022 & 2031: Understand the Magnitude of Myelofibrosis by MIPSS70+ v2.0 Risk Categories, Mutations, and Anemia – ResearchAndMarkets.com




8MM Myelofibrosis Epidemiology Analysis and Forecast 2021-2022 & 2031: Understand the Magnitude of Myelofibrosis by MIPSS70+ v2.0 Risk Categories, Mutations, and Anemia – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.

In the 8MM, diagnosed incident cases of MF (sum of the diagnosed incident cases of PMF and SMF) are expected to increase from 12,276 cases in 2021 to 15,009 cases in 2031, at an Annual Growth Rate (AGR) of 2.23%.

In 2031, China will have the highest number of diagnosed incident cases of MF in the 8MM, with 9,302 cases, whereas Spain will have the fewest diagnosed incident cases of MF with 413 cases.

In the 8MM, the diagnosed prevalent cases of MF (sum of the diagnosed prevalent cases of PMF and SMF) are expected to increase from 69,236 cases in 2021 to 84,311 cases in 2031, at an AGR of 2.18%.

The publisher’s epidemiologists attribute the increase in the diagnosed incident cases and diagnosed prevalent cases of MF to changes in the diagnosed incidence and survival rates, and population dynamics in each market.

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for MF in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of MF, PMF, PET MF, and PPV MF based on county-specific studies published in peer-reviewed journals. The diagnosed incident cases of PMF are further segmented by sex, age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years), the mutation-enhanced international prognostic scoring system (MIPSS70+) version 2.0 [very low risk (0 points), low risk (1-2 points), intermediate risk (3-4 points), high risk (5-8 points), and very high risk (=9 points)], mutations (JAK2V617F, CALR, and MPL), and anemia (with or without). The diagnosed prevalent cases of PMF are segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years). The publisher’s epidemiologists also provide sex-specific diagnosed incident and diagnosed prevalent cases of PET MF and PPV MF in the 8MM for the forecast period.
  • The myelofibrosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the global myelofibrosis market.
  • Quantify patient populations in the global myelofibrosis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for myelofibrosis therapeutics in each of the markets covered.
  • Understand magnitude of myelofibrosis by MIPSS70+ v2.0 risk categories, mutations, and anemia

Key Topics Covered:

1 Myelofibrosis: Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 8MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Diagnosed incident cases of PMF

2.4.4 Diagnosed incident cases of PET MF and PPV MF

2.4.5 MIPSS70+ V2.0 risk categories among diagnosed PMF incident cases

2.4.6 Mutations among the diagnosed incident cases of PMF

2.4.7 Patients with/without anemia among the diagnosed incident cases of PMF

2.4.8 Diagnosed prevalent cases of PMF

2.4.9 Diagnosed prevalent cases of PET MF and PPV MF

2.5 Epidemiological forecast of myelofibrosis (2021-31)

2.5.1 Diagnosed incident cases of PMF

2.5.2 Age-specific diagnosed incident cases of PMF

2.5.3 Sex-specific diagnosed incident cases of PMF

2.5.4 Diagnosed incident cases of PMF by MIPSS70+ V2.0 risk category

2.5.5 Diagnosed incident cases of PMF by mutation

2.5.6 Patients with or without anemia among diagnosed incident cases of PMF

2.5.7 Diagnosed incident cases of PET MF

2.5.8 Sex-specific diagnosed incident cases of PET MF

2.5.9 Diagnosed incident cases of PPV MF

2.5.10 Sex-specific diagnosed incident cases of PPV MF

2.5.11 Diagnosed prevalent cases of PMF

2.5.12 Age-specific diagnosed prevalent cases of PMF

2.5.13 Sex-specific diagnosed prevalent cases of PMF

2.5.14 Diagnosed prevalent cases of PET MF

2.5.15 Sex-specific diagnosed prevalent cases of PET MF

2.5.16 Diagnosed prevalent cases of PPV MF

2.5.17 Sex-specific diagnosed prevalent cases of PPV MF

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 COVID-19 impact

2.6.3 Limitations of the analysis

2.6.4 Strengths of the analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/6l57ev

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900